Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate for consciousness in hypoxic ischemic encephalopathy
IRCT20220924056025N1Phase 3Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of methylphenidate in hypoxic-ischemic encephalopathy (HIE), sponsored by Qazvin University of Medical Sciences. Started Nov 2022; status: completed.
02
Drugs
methylphenidate
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on IRCT20220924056025N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220924056025N1.